Biocompatibility Assessment
Biocompatibility Assessment - Related Videos
03:47
Implantation of a Flexible Biocompatible Probe in a Glioblastoma Mouse Model
0 Views •
2025
Source: Lefevre, M. C., et al., Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma. J. Vis. Exp. (2022)This video demonstrates the implantation of a flexible, biocompatible probe in a glioblastoma mouse model to deliver targeted pulsed electric field therapy for neurotherapeutic applications.
10:15
The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
0 Views •
Cited by 17 •
2014
Blood exposure to polymeric blood conduits initiates the foreign body reaction that has been implicated in clinical complications. Here, the Chandler Loop Apparatus, an experimental tool mimicking blood perfusion through these conduits, is described. Appendage of recombinant CD47 results in decreased evidence of the foreign body reaction on these conduits.
13:38
Synthesis of Biocompatible Liquid Crystal Elastomer Foams as Cell Scaffolds for 3D Spatial Cell Cultures
0 Views •
Cited by 9 •
2017
This study presents a methodology to prepare 3D, biodegradable, foam-like cell scaffolds based on biocompatible side-chain liquid crystal elastomers (LCEs). Confocal microscopy experiments show that foam-like LCEs allow for cell attachment, proliferation, and the spontaneous alignment of C2C12s myoblasts.
08:09
Methionine Functionalized Biocompatible Block Copolymers for Targeted Plasmid DNA Delivery
0 Views •
Cited by 1 •
2019
This work presents the preparation of methionine functionalized biocompatible block copolymers (mBG) via the reversible addition-fragmentation chain transfer (RAFT) method. The plasmid DNA complexing ability of the obtained mBG and their transfection efficiency were also investigated. The RAFT method is very beneficial for polymerizing monomers containing special functional groups.
08:26
Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
0 Views •
Cited by 13 •
2020
Laryngotracheal stenosis results from pathologic scar deposition that critically narrows the tracheal airway and lacks effective medical therapies. Using a PLLA-PCL (70% poly-L-lactide and 30% polycaprolactone) stent as a local drug delivery system, potential therapies aimed at decreasing scar proliferation in the trachea can be studied.
FAQs
Material characteristics can affect how cells, tissues, blood, and other biological systems respond to a biomedical technology. The assessment links those characteristics with outcomes such as cytotoxicity, inflammation, irritation, sensitization, hemocompatibility, and degradation. This relationship helps researchers identify potentially harmful features and determine whether changes in composition or surface properties improve the material’s biological performance.
Biological responses depend partly on how a material, device, or engineered tissue contacts living systems. Assessments therefore examine responses under exposure conditions relevant to the intended use rather than treating every application identically. Considering those conditions makes findings more meaningful for judging safety and suitability and helps reveal effects that could be missed under less representative testing conditions.
The evaluated endpoints may include cytotoxicity, inflammation, irritation, sensitization, hemocompatibility, and material degradation. Together, these measures address different types of interaction between an engineered material and living systems. Examining multiple responses provides a broader basis for identifying harmful effects, rather than relying on a single cellular or tissue outcome.
Material degradation is an important endpoint because changes in a biomaterial over time can be associated with biological responses. Evaluating degradation alongside effects such as cytotoxicity, inflammation, or irritation helps connect material changes with potential safety concerns. This information can guide composition or surface modifications and support decisions about whether the technology is appropriate for its intended use.
A typical assessment begins by considering the material, medical device, or engineered tissue and its intended exposure conditions. Researchers then select relevant laboratory evaluations and, when appropriate, biological tests for endpoints such as cellular toxicity, inflammation, irritation, sensitization, blood compatibility, and degradation. They interpret the combined findings to guide development, modification, and safety decisions.
Results can reveal which material properties are associated with unfavorable cellular, tissue, or blood responses. Bioengineers use that information to modify a material’s composition or surface and then evaluate whether the changes improve biological compatibility. This iterative use of evidence supports safer device development and can help move engineered technologies toward clinical translation.
For engineered tissues and medical devices, biological performance must be considered alongside the intended design and use. Assessment provides evidence about how the technology interacts with living systems, including possible toxic, inflammatory, irritating, sensitizing, blood-related, or degradation-related effects. These findings inform development decisions and can contribute to regulatory evaluation and the broader clinical translation of bioengineering technologies.